Pulmonary hypertension

Cite this article as:
Marc Anders. Pulmonary hypertension, Don't Forget the Bubbles, 2013. Available at:
https://doi.org/10.31440/DFTB.3731

Definition: systolic PAP >35 mmHg or mean PAP >25 mmHg, clinically if systolic PAP:systolic BP <0.5

WHO Classification
I. Pulmonary arterial hypertension
I.1 Idiopathic
I.2 Familial
I.3 Associated with collagen vascular disease, portal hypertension, HIV, drugs & toxins, congenital systemic-pulmonary shunts, others
I.4 Persistent PHT in the Newborn
I.5 Pulmonary veno-occlusive disease
II. Pulmonary hypertension w/ left heart disease:left sided atrial, valvular or ventricular disease (TAPVR, MS, AS, Coarctation)
III. PHT associated with disorders of the respiratory system: COPD, sleep apnea, central hypoventilation Syndrome, high altitude, CLD
IV. PHT due to chronic thrombotic or embolic events
V. Miscs: sarcoidosis, histiocytosis, others

Diagnosis:

  • PA pressure: most reliable, invasive line
  • LA pressure: differential diagnosis – LV dysfunction
  • Echocardiography: measurement of TR jet velocity (modified Bernoulli equation: RVSP = 4 * v2 + RAP), movement of the interventricular septum, identify anatomical problems
  • Cardiac catheterisation: right heart catheter (mPAP >25 mmHg or PVR >3 Wood units/m2) → vasodilator therapy challenge to guide further therapy
  • Cardiac MRI: RV structure and function (limited in neonates)
  • High resolution chest CT with contrast: parenchymal lung disease, thromboembolism, others

Physiology:

Increase in RV afterload → RV volume and pressure increase → RV systolic dysfunction (→ TR) and diastolic dysfunction (→ RV diastolic HTN → increased right to left shunt if exists → hypoxia) → reduced RV output → reduced LV filling → reduced CO and reduced coronary artery perfusion pressure → RV ischemia and ventricular interdependence → RV systolic dysfunction


Neonatal PHT:

Incidence 2:1000, most common due to MAS, RDS, pneumonia, also idiopathic or in congenital diaphragmatic hernia


Postoperative PHT:

  • Preoperative predisposition: increased PVR, increased PBF, increased PVR and PBF, increased pulmonary venous pressure, lesion related (TAPVD, AVSD, VSD, IAA, truncus, shunt ops)
  • Cardiopulmonary bypass: decreased NO production, ischaemia-reperfusion injury, attendant inflammatory response (thromboxane, microemboli, leucosequestration, HPV)
  • Standard cardiovascular monitoring: early signs are tachycardia and hypotension; hypoxia occurs early only due to intracardiac shunts or as a late sign

Prophylaxis for postoperative PHT:

Maintain adequate analgesia and sedation (fentanyl 1 mcg/kg IV before painful stimuli), consider paralysis, normothermia, normal pH, aim paCO2 30-35 mmHg, paO2>75 mmHg in non-cyanotic lesion, prevent hyper- and hypoinflation, minimise intrathoracic pressures, consider milrinone infusion, consider iNO


Therapy for acute PHT crisis:

  • Increase FiO2 to 1.0: O2 is the best pulmonary vasodilator
  • Support cardiac output:resuscitation if required, dopamine (5-10 mcg/kg/min), dobutamine (5-10 mcg/kg/min), adrenaline (0.02-0.1 mcg/kg/min), milrinone (0.25-0.75 mcg/kg/min) as a PDE3 inhibitor increases cAMP → PVR vasodilation
  • NO donator: increased cGMP → vasodilation: commence NO 20 ppm, SNP (0.5-4 mcg/kg/min), GTN (0.5-5 mcg/kg/min)
  • Prostacyclin (= prostaglandin I2 = epoprostenol): increased cAMP → vasodilation, commence infusion (5-15 ng/kg/min), or nebulised; half-life: 3 min., can increase PBF and promote pulmonary oedema
  • Surfactant in neonates: promotes lung expansion, commence stat dose of poractant alpha (200 mg/kg)
  • Consider HFO: promotes lung expansion, avoid hyperinflation
  • Consider ECMO

Therapy for chronic PHT:

  • Sildenafil: (PDE5 inhibitor → increased cGMP), test dose 0.1 mg/kg, then increase slowly to maximum 2 mg/kg q4hr. FDA recommends against the use in sildenafil in chronic PHT in children, as lower doses were not effective, higher doses increased mortality. The implication its use in PICU is unclear.
  • Prostacyclin
  • Bosentan (1 mg/kg BD, increase to 2 mg/kg BD after 4 weeks)
  • Lung transplantation

References:

[1] Pediatr Crit Care Med. 2010 Mar;11(2 Suppl):S79-84: Steinhorn: Neonatal pulmonary hypertension

[2] Pediatr Crit Care Med. 2010 Mar;11(2 Suppl):S27-9: Taylor et al: Fundamentals of management of acute postoperative pulmonary hypertension

[3] Pediatr Crit Care Med. 2010 Mar;11(2 Suppl):S23-6: Mullen: Diagnostic strategies for acute presentation of pulmonary hypertension in children: particular focus on use of echocardiography, cardiac catheterization, magnetic resonance imaging, chest computed tomography, and lung biopsy

[4] Pediatr Crit Care Med. 2010 Mar;11(2 Suppl):S15-22: Bronicki et al: Pathophysiology of right ventricular failure in pulmonary hypertension

[5] Pediatr Crit Care Med. 2010 Mar;11(2 Suppl):S30-6: Barr et al: Inhaled nitric oxide and related therapies

[6] Pediatr Crit Care Med. 2010 Mar;11(2 Suppl):S41-5: Ivy: Prostacyclin in the intensive care setting

[7] Pharmacotherapy. 2010 Jul;30(7):728-40: Buckley et al: Inhaled epoprostenol for the treatment of pulmonary arterial hypertension in critically ill adults


All Marc’s PICU cardiology FOAM can be found on PICU Doctor and can be downloaded as a handy app for free on iPhone or AndroidA list of contributors can be seen here.

If you enjoyed this post, why not check out our online courses at DFTB Digital

About Marc Anders

AvatarMarc Anders is a paediatric intensivist.

Avatar
Author: Marc Anders Marc Anders is a paediatric intensivist.

Leave a Reply